FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 294-262 PCT/US	SERIAL NO. 10/594,382
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Schwartz-Albiez, et al.	CONFIRMATION NO. Unassigned
(Use several sheets if necessary)	FILING DATE September 26, 2006	GROUP Unassigned

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	TRANSLATION NO
		DE 102 45 927 A	04/15/2004	Germany				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Theunissen, et al., "Long-term engrafting umbilical cord blood cells are preserved after ex vivo culture in stroma-free culture," *Online!* May 2001, http://mmserver.cjp.com/ gems/blood/ABMT.10.verfaillie.pdf, pgs 599-603.
		Pankaj, et al., "Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with o-sulfated heparin sulfates: Requirement for optimal binding interactions of heparin sulfate with early-acting cytokines and matrix proteins," *Blood* January 2000, 95(1):147-155.
		Pankaj, et al., "Structurally specific heparin sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche," *Blood* December 1998, 92(12):4641-4651.
		Lewis, et al., "Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system," *Blood* June 2001, 97(11):3441-3449.
		Schubert, "Einfluss regioselektiv modifizierter Heparansulfate auf den Erhalt and die Expansion primitiver hamatopoietischer Stammzelle and Vorlauferzellen," *Online!* 2004, http://doctor-schubert.de/downloads/Dissertation%20M.Schubert.pdf.

EXAMINER /Leon Lankford Jr/ DATE CONSIDERED 06/19/2011

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.L./

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 294-262 PCT/US	SERIAL NO. 10/594,382
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Schwartz-Albiez, et al.	CONFIRMATION NO. Unassigned
(Use several sheets if necessary)	FILING DATE September 26, 2006	GROUP Unassigned

			Punzel, et al., "The microenvironment of AFT024 cells maintains primitive human hematopoiesis by counteracting contact mediated inhibition of proliferation." *Cell Communication & Adhesion*, May-June 2002, 9(3):149-159.
			Gupta, et al., "Artificial 'proteoglycan-like' molecules containing heparin sulfate enhance the ability of cytokines to maintain human hematopoietic stem cells in vitro," *Journal of Investigative Medicine*, 1995, 43(SUPPL2):342A.
			Moore, et al., "In vitro maintenance of highly purified, transplantable hematopoietic stem cells," *Blood*, 1997, 89(12):4337-4347.
			Moore, et al., "Hematopoietic Activity of a Stromal Cell Transmembrane Protein Containing Epidermal Growth Factor-Like Repeat Motifs," *Proceedings of the National Academy of Sciences of USA*, April 1997, 94:4011-4016.
			Stringer, et al., "Identification of an MIP-1alpha-binding heparin sulfate oligosaccharide that supports long-term in vitro maintenance of human LTC-ICs," *Blood*, March 2003, 101(6):2243-2245.

231578_1

EXAMINER /Leon Lankford Jr/ DATE CONSIDERED 06/19/2011

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.L./